Hyperbaric Oxygen for Carbon Monoxide Poisoning
- 27 Downloads
Poisoning with carbon monoxide (CO) is an important cause of unintentional and intentional injury worldwide. Hyperbaric oxygen (HBO) enhances CO elimination and has been postulated to reduce the incidence of neurological sequelae. These observations have led some clinicians to use HBO for selected patients with CO poisoning, although there is considerable variability in clinical practice.
This article assesses the effectiveness of HBO compared with normobaric oxygen (NBO) for the prevention of neurological sequelae in patients with acute CO poisoning. The following databases were searched: MEDLINE (1966 to present), EMBASE (1980 to present), and the Controlled Trials Register of the Cochrane Collaboration, supplemented by a manual review of bibliographies of identified articles and discussion with recognised content experts.
All randomised controlled trials involving people acutely poisoned with CO, regardless of severity, were examined. The primary analysis included all trials from which data could be extracted. Sensitivity analysis examined trials with better validity (defined using the validated instrument of Jadad) and those enrolling more severely poisoned patients.
Two reviewers independently extracted from each trial, including information on the number of randomised patients, types of participants, the dose and duration of the intervention, and the prevalence of neurological sequelae at follow-up. A pooled odds ratio (OR) for the presence of neurological symptoms at 1-month follow-up was calculated using a random effects model. Bayesian models were also investigated to illustrate the degree of certainty about clinical effectiveness.
Eight randomised controlled trials were identified. Two had no evaluable data and were excluded. The remaining trials were of varying quality and two have been published only as abstracts. The severity of CO poisoning varied among trials. At 1-month follow-up after treatment, sequelae possibly related to CO poisoning were present in 242 of 761 patients (36.1%) treated with NBO, compared with 259 of 718 patients (31.8%) treated with HBO. Restricting the analysis to the trials with the highest quality scores or those that enrolled all patients regardless of severity did not change the lack of statistical significance in the outcome of the pooled analysis. We found empiric evidence of multiple biases that operated to inflate the benefit of HBO in two positive trials. In contrast, the interpretation of negative trials was hampered by low rates of follow-up, unusual interventions for control patients and inclusion of less severely poisoned patients. Collectively, these limitations may have led negative trials to overlook a real and substantial benefit of HBO (type II error).
There is conflicting evidence regarding the efficacy of HBO treatment for patients with CO poisoning. Methodological shortcomings are evident in all published trials, with empiric evidence of bias in some, particularly those that suggest a benefit of HBO. Bayesian analysis further illustrates the uncertainty about a meaningful clinical benefit. Consequently, firm guidelines regarding the use of HBO for patients with CO poisoning cannot be established. Further research is needed to better define the role of HBO, if any, in the treatment of CO poisoning. Such research should not exclude patients with severe poisoning, have a primary outcome that is clinically meaningful and have oversight from an independent data monitoring and ethics committee.
KeywordsInterim Analysis Hyperbaric Oxygen Allocation Concealment Neurological Sequela Hyperbaric Chamber
Parts of this review have been published as a Cochrane review (see Juurlink et al.[]). David Juurlink is supported by a New Investigator Award from the Canadian Institutes of Health Research, and by the University of Toronto Drug Safety Research Group. Geoffrey Isbister is supported by an NHMRC Clinical Career Development Award ID300785. The authors have no conflicts of interest.
- 8.Juurlink DN, Stanbrook MB, McGuigan MA. Hyperbaric oxygen for carbon monoxide poisoning. Cochrane Database Syst Rev 2000; (2): CD002041Google Scholar
- 10.Raphael JC, Chevret S, Driheme A, et al. Managing carbon monoxide poisoning with hyperbaric oxygen. Proceedings of the European Association of Poisons Centres and Clinical Toxicologists (EAPCCT); 2004 Jun 3; Strasbourg, 49–50Google Scholar
- 11.Hampson NB, Dunford RG, Ross DE, et al. A prospective, randomized clinical trial comparing two hyperbaric treatment protocols for carbon monoxide poisoning. Undersea Hyperbaric Medicine Society Annual Scientific Meeting; 2004 May 29; SydneyGoogle Scholar
- 15.Mathieu D, Wattel F, Mathieu-Nolf M, et al. Randomized prospective study comparing the effect of HBO vs. 12 hours NBO in non-comatose CO-poisoned patients: results of preliminary analysis. Undersea Hyperb Med 1996; 23 Suppl.: 7–8Google Scholar
- 16.Scheinkestel CD, Jones K, Cooper DJ, et al. Interim analysis: controlled clinical trial of hyperbaric oxygen in acute carbon monoxide (CO) poisoning. Undersea Hyperb Med 1996; 23 Suppl.: 7Google Scholar
- 17.Thom SR, Taber RL, Mendiguren II, et al. Delayed neuropsychologic sequelae following CO poisoning and the role of treatment with 100% O2 or hyperbaric oxygen: a prospective randomized, clinical study. Undersea Biomed Res 1992; 19 Suppl.: 47Google Scholar
- 18.Weaver LK, Hopkins RO, Larson-Lohr V, et al. Double blind, controlled, prospective, randomized clinical trial (RCT) in patients with acute carbon monoxide (CO) poisoning: outcome of patients treated with normobaric oxygen or hyperbaric oxygen (HBO): an interim report. Undersea Hyperb Med 1995; 22 Suppl.: 14Google Scholar
- 24.Juurlink D, Buckley N, Stanbrook M, et al. Hyperbaric oxygen for carbon monoxide poisoning. Cochrane Database Syst Rev 2005; (1): CD002041Google Scholar